Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial [PDF]
Infectious Diseases and Therapy, 2018 Introduction Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations.
Richard G. Wunderink +22 more
doaj +3 more sources
Infectious Diseases and Therapy, 2020 Plain Language Summary Meropenem-vaborbactam is a new combination antibiotic that was designed specifically for efficacy against bacteria that produce the Klebsiella pneumoniae carbapenemase (KPC) enzyme, which enables resistance to beta-lactam ...
Tanaya Bhowmick
exaly +2 more sources
In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii [PDF]
Scientific ReportsTreatment of carbapenem-resistant Acinetobacter baumannii (CRAB) presents a growing clinical challenge. This study evaluated the in vitro efficacy of eravacycline and the potential synergistic activity of meropenem-vaborbactam in combination with either ...
Amira H. El-Ashry +4 more
doaj +2 more sources
Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy [PDF]
Pharmaceutics, 2023 Outpatient parenteral antimicrobial therapy (OPAT) is a useful treatment strategy against Pseudomonas aeruginosa and other multidrug-resistant bacteria.
Beatriz Fernández-Rubio +9 more
doaj +3 more sources
The European Medicines Agency Approved the New Antibacterial Drugs – Response to the 2017 Who Report on the Global Problem of Multi-Drug Resistance [PDF]
Postępy Mikrobiologii, 2021 The growing problem of antimicrobial resistance has been classified by the World Health Organization (WHO) as one of the top ten threats to mankind. In a special report published in 2017, the WHO presented a list of microorganisms for which the search ...
Krajewska Joanna, Laudy Agnieszka Ewa
doaj +2 more sources
PLoS ONE, 2021 Antimicrobial resistance (AMR) mediated by β-lactamases is the major and leading cause of resistance to penicillins and cephalosporins among Gram-negative bacteria.
Vijay Kumar +5 more
doaj +3 more sources
Microbiology Spectrum, 2023 Carbapenems are a common first-line therapy for serious Gram-negative infections, but carbapenem-resistant Enterobacterales (CRE) isolates have become an urgent health concern. Klebsiella pneumoniae serine carbapenemases (KPCs) now have been disseminated
Dee Shortridge +2 more
doaj +1 more source
Ultra-performance liquid chromatography-tandem mass spectrometric method for quantitation of the recently Food and Drug Administration approved combination of vaborbactam and meropenem in human plasma [PDF]
Royal Society Open Science, 2020 A parenteral medical combination containing vaborbactam and meropenem is used mainly to treat complicated urinary tract infections. A novel ultra-performance liquid chromatography tandem mass spectrometric method was developed for the sensitive ...
Ahmed K. Kammoun +3 more
doaj +1 more source
Antibiotics, 2021 Meropenem/Vaborbactam (MEM-VAB) is a novel carbapenem- β-lactamase inhibitor active against KPC-producing Enterobacteria. Herein, we evaluate the incidence of meropenem/vaborbactam-resistance among KPC-producing K.
Paolo Gaibani +9 more
doaj +1 more source
Antibiotics, 2023 Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to aztreonam.
Cécile Emeraud +2 more
doaj +1 more source